Cancer Science • Vol 114 • No 5
Development of an osteosarcoma model with <i>MYCN</i> amplification and <i>TP53</i> mutation in hiPS cell‐derived neural crest cells
January 2023 • Kyosuke Mukae, Hisanori Takenobu, Yuki Endo, Masayuki Haruta, Tianyuan Shi, Shunpei Satoh, Miki Ohira, Michinori Funato, Junya Toguchida, Kenji Osafu…
Abstract Mesenchymal stem cell‐ or osteoblast‐derived osteosarcoma is the most common malignant bone tumor. Its highly metastatic malignant phenotypes, which are often associated with a poor prognosis, have been correlated with the modulation of TP53‐ and cell‐cycle‐related pathways. MYC, which regulates the transcription of cell‐cycle modulating genes, is used as a representative prognostic marker for osteosarcoma. Another member of the MYC oncoprotein family, MYCN, is highly expressed in a subset of osteosarcoma…